GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifeline Scientific Inc (LSE:LSI) » Definitions » Institutional Ownership

Lifeline Scientific (LSE:LSI) Institutional Ownership : 2.00% (As of Jun. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Lifeline Scientific Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lifeline Scientific's institutional ownership is 2.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lifeline Scientific's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lifeline Scientific's Float Percentage Of Total Shares Outstanding is 0.00%.


Lifeline Scientific Institutional Ownership Historical Data

The historical data trend for Lifeline Scientific's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifeline Scientific Institutional Ownership Chart

Lifeline Scientific Historical Data

The historical data trend for Lifeline Scientific can be seen below:

2011-06-30 2011-12-31 2013-03-31 2013-06-30 2013-09-30 2013-12-31 2014-03-31 2014-06-30 2014-09-30
Institutional Ownership 1.00 1.00 1.00 1.00 2.00 2.00 2.00 2.00 2.00

Lifeline Scientific Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Lifeline Scientific (LSE:LSI) Business Description

Traded in Other Exchanges
N/A
Address
Lifeline Scientific Inc was incorporated on October 1, 1998. The Company is in the business of delivering, to targeted medical markets, a portfolio of related proprietary technologies, which include devices, solutions, and protocols designed to maximize the use and availability of organs, tissues, and cells. It serves the kidney transplant market today with its LifePort product line, and also sells solutions to service the broader organ transplant industry. The Company operates in North America, Brazil, China and Rest of World.